Skip to content
2024
SYSTEMIC DELIVERY, LOCAL ACTIVITY

Press Releases

Bonum Therapeutics Announces a $93M Series A Financing to Advance a Novel and Validated Class of Conditionally Active Therapies

“We believe that this technology has broad potential and we are excited to apply it in new areas…”

Good Therapeutics Announces Acquisition of Conditionally Active PD-1-Regulated IL-2 Program by Roche

“Given Roche’s expertise in this field and broad capabilities in oncology, we believe they are a perfect choice for taking this important program forward…”

In the news

GeekWire

Seattle biotech startup born out of a Roche buyout lands $93M to advance therapies

Media

Genetic Engineering & Biotechnology News

From Good to Great: Bonum Therapeutics Raises $93M Series A with Allosterically Regulated Medicines

Media

Endpoints News

The crew that sold its lead IL-2 program to Roche is back with $93M to work on more next-gen I/O drugs

Media

Biocentury

Sequel company Bonum emerges in wake of Roche’s Good Tx acquisition

Media

BioWorld

Bonum to continue Good work after $250M cash acquisition deal with Roche

Media

Also seen in

Drug Discovery World

How to Get the Biopharma Deal You Want

Media

BioSpace

NextGen Class of 2024: Top Life Sciences Startups to Watch This Year

Media

Business of Biotech Podcast

IL-2 Program with Bonum’s Drs. John Mulligan and Neela Patel

Media

Rivervest

From Good to Great: Unlocking a biopharma platform’s full potential

Media

The Bio Report Podcast

Realizing the Therapeutic Potential of Cytokines by Making them Context Dependent

Media

Life Science Leader

A Recipe for Start-Up Success with a Platform Technology

Media

In Vivo Pharma Intelligence

The Busiest Dealmakers of 2022

Media

Puget Sound Business Journal

Seattle biotech Bonum raises $93M Series A round

Media

Blog

A BD Checklist: Best Practices for Partnering with Pharma

Blog

Should My Biotech Startup Buy Or Produce The Proteins We Use?

Blog

Developing the Next Generation of Targeted, Conditionally Active Cytokine Therapeutics

Blog

Founder & CEO John Mulligan Shares Bonum Therapeutics’ “No Jerks” Approach to Hiring

Blog

6 Tips for Successful Drug Discovery Teamwork

Blog
2024
SYSTEMIC DELIVERY, LOCAL ACTIVITY

Press Releases

Bonum Therapeutics Announces a $93M Series A Financing to Advance a Novel and Validated Class of Conditionally Active Therapies

“We believe that this technology has broad potential and we are excited to apply it in new areas…”

Good Therapeutics Announces Acquisition of Conditionally Active PD-1-Regulated IL-2 Program by Roche

“Given Roche’s expertise in this field and broad capabilities in oncology, we believe they are a perfect choice for taking this important program forward…”

In the news

GeekWire

Seattle biotech startup born out of a Roche buyout lands $93M to advance therapies

Media

Genetic Engineering & Biotechnology News

From Good to Great: Bonum Therapeutics Raises $93M Series A with Allosterically Regulated Medicines

Media

Endpoints News

The crew that sold its lead IL-2 program to Roche is back with $93M to work on more next-gen I/O drugs

Media

Biocentury

Sequel company Bonum emerges in wake of Roche’s Good Tx acquisition

Media

BioWorld

Bonum to continue Good work after $250M cash acquisition deal with Roche

Media

Also seen in

Drug Discovery World

How to Get the Biopharma Deal You Want

Media

BioSpace

NextGen Class of 2024: Top Life Sciences Startups to Watch This Year

Media

Business of Biotech Podcast

IL-2 Program with Bonum’s Drs. John Mulligan and Neela Patel

Media

Rivervest

From Good to Great: Unlocking a biopharma platform’s full potential

Media

The Bio Report Podcast

Realizing the Therapeutic Potential of Cytokines by Making them Context Dependent

Media

Life Science Leader

A Recipe for Start-Up Success with a Platform Technology

Media

In Vivo Pharma Intelligence

The Busiest Dealmakers of 2022

Media

Puget Sound Business Journal

Seattle biotech Bonum raises $93M Series A round

Media

Blog

A BD Checklist: Best Practices for Partnering with Pharma

Blog

Should My Biotech Startup Buy Or Produce The Proteins We Use?

Blog

Developing the Next Generation of Targeted, Conditionally Active Cytokine Therapeutics

Blog

Founder & CEO John Mulligan Shares Bonum Therapeutics’ “No Jerks” Approach to Hiring

Blog

6 Tips for Successful Drug Discovery Teamwork

Blog
2024
SYSTEMIC DELIVERY, LOCAL ACTIVITY

Press Releases

Bonum Therapeutics Announces a $93M Series A Financing to Advance a Novel and Validated Class of Conditionally Active Therapies

“We believe that this technology has broad potential and we are excited to apply it in new areas…”

Good Therapeutics Announces Acquisition of Conditionally Active PD-1-Regulated IL-2 Program by Roche

“Given Roche’s expertise in this field and broad capabilities in oncology, we believe they are a perfect choice for taking this important program forward…”

In the news

GeekWire

Seattle biotech startup born out of a Roche buyout lands $93M to advance therapies

Media

Genetic Engineering & Biotechnology News

From Good to Great: Bonum Therapeutics Raises $93M Series A with Allosterically Regulated Medicines

Media

Endpoints News

The crew that sold its lead IL-2 program to Roche is back with $93M to work on more next-gen I/O drugs

Media

Biocentury

Sequel company Bonum emerges in wake of Roche’s Good Tx acquisition

Media

BioWorld

Bonum to continue Good work after $250M cash acquisition deal with Roche

Media

Also seen in

Drug Discovery World

How to Get the Biopharma Deal You Want

Media

BioSpace

NextGen Class of 2024: Top Life Sciences Startups to Watch This Year

Media

Business of Biotech Podcast

IL-2 Program with Bonum’s Drs. John Mulligan and Neela Patel

Media

Rivervest

From Good to Great: Unlocking a biopharma platform’s full potential

Media

The Bio Report Podcast

Realizing the Therapeutic Potential of Cytokines by Making them Context Dependent

Media

Life Science Leader

A Recipe for Start-Up Success with a Platform Technology

Media

In Vivo Pharma Intelligence

The Busiest Dealmakers of 2022

Media

Puget Sound Business Journal

Seattle biotech Bonum raises $93M Series A round

Media

Blog

A BD Checklist: Best Practices for Partnering with Pharma

Blog

Should My Biotech Startup Buy Or Produce The Proteins We Use?

Blog

Developing the Next Generation of Targeted, Conditionally Active Cytokine Therapeutics

Blog

Founder & CEO John Mulligan Shares Bonum Therapeutics’ “No Jerks” Approach to Hiring

Blog

6 Tips for Successful Drug Discovery Teamwork

Blog
2024
SYSTEMIC DELIVERY, LOCAL ACTIVITY

Press Releases

Bonum Therapeutics Announces a $93M Series A Financing to Advance a Novel and Validated Class of Conditionally Active Therapies

“We believe that this technology has broad potential and we are excited to apply it in new areas…”

Good Therapeutics Announces Acquisition of Conditionally Active PD-1-Regulated IL-2 Program by Roche

“Given Roche’s expertise in this field and broad capabilities in oncology, we believe they are a perfect choice for taking this important program forward…”

In the news

GeekWire

Seattle biotech startup born out of a Roche buyout lands $93M to advance therapies

Media

Genetic Engineering & Biotechnology News

From Good to Great: Bonum Therapeutics Raises $93M Series A with Allosterically Regulated Medicines

Media

Endpoints News

The crew that sold its lead IL-2 program to Roche is back with $93M to work on more next-gen I/O drugs

Media

Biocentury

Sequel company Bonum emerges in wake of Roche’s Good Tx acquisition

Media

BioWorld

Bonum to continue Good work after $250M cash acquisition deal with Roche

Media

Also seen in

Drug Discovery World

How to Get the Biopharma Deal You Want

Media

BioSpace

NextGen Class of 2024: Top Life Sciences Startups to Watch This Year

Media

Business of Biotech Podcast

IL-2 Program with Bonum’s Drs. John Mulligan and Neela Patel

Media

Rivervest

From Good to Great: Unlocking a biopharma platform’s full potential

Media

The Bio Report Podcast

Realizing the Therapeutic Potential of Cytokines by Making them Context Dependent

Media

Life Science Leader

A Recipe for Start-Up Success with a Platform Technology

Media

In Vivo Pharma Intelligence

The Busiest Dealmakers of 2022

Media

Puget Sound Business Journal

Seattle biotech Bonum raises $93M Series A round

Media

Blog

A BD Checklist: Best Practices for Partnering with Pharma

Blog

Should My Biotech Startup Buy Or Produce The Proteins We Use?

Blog

Developing the Next Generation of Targeted, Conditionally Active Cytokine Therapeutics

Blog

Founder & CEO John Mulligan Shares Bonum Therapeutics’ “No Jerks” Approach to Hiring

Blog

6 Tips for Successful Drug Discovery Teamwork

Blog
2024
SYSTEMIC DELIVERY, LOCAL ACTIVITY

Press Releases

Bonum Therapeutics Announces a $93M Series A Financing to Advance a Novel and Validated Class of Conditionally Active Therapies

“We believe that this technology has broad potential and we are excited to apply it in new areas…”

Good Therapeutics Announces Acquisition of Conditionally Active PD-1-Regulated IL-2 Program by Roche

“Given Roche’s expertise in this field and broad capabilities in oncology, we believe they are a perfect choice for taking this important program forward…”

In the news

GeekWire

Seattle biotech startup born out of a Roche buyout lands $93M to advance therapies

Media

Genetic Engineering & Biotechnology News

From Good to Great: Bonum Therapeutics Raises $93M Series A with Allosterically Regulated Medicines

Media

Endpoints News

The crew that sold its lead IL-2 program to Roche is back with $93M to work on more next-gen I/O drugs

Media

Biocentury

Sequel company Bonum emerges in wake of Roche’s Good Tx acquisition

Media

BioWorld

Bonum to continue Good work after $250M cash acquisition deal with Roche

Media

Also seen in

Drug Discovery World

How to Get the Biopharma Deal You Want

Media

BioSpace

NextGen Class of 2024: Top Life Sciences Startups to Watch This Year

Media

Business of Biotech Podcast

IL-2 Program with Bonum’s Drs. John Mulligan and Neela Patel

Media

Rivervest

From Good to Great: Unlocking a biopharma platform’s full potential

Media

The Bio Report Podcast

Realizing the Therapeutic Potential of Cytokines by Making them Context Dependent

Media

Life Science Leader

A Recipe for Start-Up Success with a Platform Technology

Media

In Vivo Pharma Intelligence

The Busiest Dealmakers of 2022

Media

Puget Sound Business Journal

Seattle biotech Bonum raises $93M Series A round

Media

Blog

A BD Checklist: Best Practices for Partnering with Pharma

Blog

Should My Biotech Startup Buy Or Produce The Proteins We Use?

Blog

Developing the Next Generation of Targeted, Conditionally Active Cytokine Therapeutics

Blog

Founder & CEO John Mulligan Shares Bonum Therapeutics’ “No Jerks” Approach to Hiring

Blog

6 Tips for Successful Drug Discovery Teamwork

Blog
2024
SYSTEMIC DELIVERY, LOCAL ACTIVITY

Press Releases

Bonum Therapeutics Announces a $93M Series A Financing to Advance a Novel and Validated Class of Conditionally Active Therapies

“We believe that this technology has broad potential and we are excited to apply it in new areas…”

Good Therapeutics Announces Acquisition of Conditionally Active PD-1-Regulated IL-2 Program by Roche

“Given Roche’s expertise in this field and broad capabilities in oncology, we believe they are a perfect choice for taking this important program forward…”

In the news

GeekWire

Seattle biotech startup born out of a Roche buyout lands $93M to advance therapies

Media

Genetic Engineering & Biotechnology News

From Good to Great: Bonum Therapeutics Raises $93M Series A with Allosterically Regulated Medicines

Media

Endpoints News

The crew that sold its lead IL-2 program to Roche is back with $93M to work on more next-gen I/O drugs

Media

Biocentury

Sequel company Bonum emerges in wake of Roche’s Good Tx acquisition

Media

BioWorld

Bonum to continue Good work after $250M cash acquisition deal with Roche

Media

Also seen in

Drug Discovery World

How to Get the Biopharma Deal You Want

Media

BioSpace

NextGen Class of 2024: Top Life Sciences Startups to Watch This Year

Media

Business of Biotech Podcast

IL-2 Program with Bonum’s Drs. John Mulligan and Neela Patel

Media

Rivervest

From Good to Great: Unlocking a biopharma platform’s full potential

Media

The Bio Report Podcast

Realizing the Therapeutic Potential of Cytokines by Making them Context Dependent

Media

Life Science Leader

A Recipe for Start-Up Success with a Platform Technology

Media

In Vivo Pharma Intelligence

The Busiest Dealmakers of 2022

Media

Puget Sound Business Journal

Seattle biotech Bonum raises $93M Series A round

Media

Blog

A BD Checklist: Best Practices for Partnering with Pharma

Blog

Should My Biotech Startup Buy Or Produce The Proteins We Use?

Blog

Developing the Next Generation of Targeted, Conditionally Active Cytokine Therapeutics

Blog

Founder & CEO John Mulligan Shares Bonum Therapeutics’ “No Jerks” Approach to Hiring

Blog

6 Tips for Successful Drug Discovery Teamwork

Blog
2024
SYSTEMIC DELIVERY, LOCAL ACTIVITY

Press Releases

Bonum Therapeutics Announces a $93M Series A Financing to Advance a Novel and Validated Class of Conditionally Active Therapies

“We believe that this technology has broad potential and we are excited to apply it in new areas…”

Good Therapeutics Announces Acquisition of Conditionally Active PD-1-Regulated IL-2 Program by Roche

“Given Roche’s expertise in this field and broad capabilities in oncology, we believe they are a perfect choice for taking this important program forward…”

In the news

GeekWire

Seattle biotech startup born out of a Roche buyout lands $93M to advance therapies

Media

Genetic Engineering & Biotechnology News

From Good to Great: Bonum Therapeutics Raises $93M Series A with Allosterically Regulated Medicines

Media

Endpoints News

The crew that sold its lead IL-2 program to Roche is back with $93M to work on more next-gen I/O drugs

Media

Biocentury

Sequel company Bonum emerges in wake of Roche’s Good Tx acquisition

Media

BioWorld

Bonum to continue Good work after $250M cash acquisition deal with Roche

Media

Also seen in

Drug Discovery World

How to Get the Biopharma Deal You Want

Media

BioSpace

NextGen Class of 2024: Top Life Sciences Startups to Watch This Year

Media

Business of Biotech Podcast

IL-2 Program with Bonum’s Drs. John Mulligan and Neela Patel

Media

Rivervest

From Good to Great: Unlocking a biopharma platform’s full potential

Media

The Bio Report Podcast

Realizing the Therapeutic Potential of Cytokines by Making them Context Dependent

Media

Life Science Leader

A Recipe for Start-Up Success with a Platform Technology

Media

In Vivo Pharma Intelligence

The Busiest Dealmakers of 2022

Media

Puget Sound Business Journal

Seattle biotech Bonum raises $93M Series A round

Media

Blog

A BD Checklist: Best Practices for Partnering with Pharma

Blog

Should My Biotech Startup Buy Or Produce The Proteins We Use?

Blog

Developing the Next Generation of Targeted, Conditionally Active Cytokine Therapeutics

Blog

Founder & CEO John Mulligan Shares Bonum Therapeutics’ “No Jerks” Approach to Hiring

Blog

6 Tips for Successful Drug Discovery Teamwork

Blog
2024
SYSTEMIC DELIVERY, LOCAL ACTIVITY

Press Releases

Bonum Therapeutics Announces a $93M Series A Financing to Advance a Novel and Validated Class of Conditionally Active Therapies

“We believe that this technology has broad potential and we are excited to apply it in new areas…”

Good Therapeutics Announces Acquisition of Conditionally Active PD-1-Regulated IL-2 Program by Roche

“Given Roche’s expertise in this field and broad capabilities in oncology, we believe they are a perfect choice for taking this important program forward…”

In the news

GeekWire

Seattle biotech startup born out of a Roche buyout lands $93M to advance therapies

Media

Genetic Engineering & Biotechnology News

From Good to Great: Bonum Therapeutics Raises $93M Series A with Allosterically Regulated Medicines

Media

Endpoints News

The crew that sold its lead IL-2 program to Roche is back with $93M to work on more next-gen I/O drugs

Media

Biocentury

Sequel company Bonum emerges in wake of Roche’s Good Tx acquisition

Media

BioWorld

Bonum to continue Good work after $250M cash acquisition deal with Roche

Media

Also seen in

Drug Discovery World

How to Get the Biopharma Deal You Want

Media

BioSpace

NextGen Class of 2024: Top Life Sciences Startups to Watch This Year

Media

Business of Biotech Podcast

IL-2 Program with Bonum’s Drs. John Mulligan and Neela Patel

Media

Rivervest

From Good to Great: Unlocking a biopharma platform’s full potential

Media

The Bio Report Podcast

Realizing the Therapeutic Potential of Cytokines by Making them Context Dependent

Media

Life Science Leader

A Recipe for Start-Up Success with a Platform Technology

Media

In Vivo Pharma Intelligence

The Busiest Dealmakers of 2022

Media

Puget Sound Business Journal

Seattle biotech Bonum raises $93M Series A round

Media

Blog

A BD Checklist: Best Practices for Partnering with Pharma

Blog

Should My Biotech Startup Buy Or Produce The Proteins We Use?

Blog

Developing the Next Generation of Targeted, Conditionally Active Cytokine Therapeutics

Blog

Founder & CEO John Mulligan Shares Bonum Therapeutics’ “No Jerks” Approach to Hiring

Blog

6 Tips for Successful Drug Discovery Teamwork

Blog
2024
SYSTEMIC DELIVERY, LOCAL ACTIVITY

Press Releases

Bonum Therapeutics Announces a $93M Series A Financing to Advance a Novel and Validated Class of Conditionally Active Therapies

“We believe that this technology has broad potential and we are excited to apply it in new areas…”

Good Therapeutics Announces Acquisition of Conditionally Active PD-1-Regulated IL-2 Program by Roche

“Given Roche’s expertise in this field and broad capabilities in oncology, we believe they are a perfect choice for taking this important program forward…”

In the news

GeekWire

Seattle biotech startup born out of a Roche buyout lands $93M to advance therapies

Media

Genetic Engineering & Biotechnology News

From Good to Great: Bonum Therapeutics Raises $93M Series A with Allosterically Regulated Medicines

Media

Endpoints News

The crew that sold its lead IL-2 program to Roche is back with $93M to work on more next-gen I/O drugs

Media

Biocentury

Sequel company Bonum emerges in wake of Roche’s Good Tx acquisition

Media

BioWorld

Bonum to continue Good work after $250M cash acquisition deal with Roche

Media

Also seen in

Drug Discovery World

How to Get the Biopharma Deal You Want

Media

BioSpace

NextGen Class of 2024: Top Life Sciences Startups to Watch This Year

Media

Business of Biotech Podcast

IL-2 Program with Bonum’s Drs. John Mulligan and Neela Patel

Media

Rivervest

From Good to Great: Unlocking a biopharma platform’s full potential

Media

The Bio Report Podcast

Realizing the Therapeutic Potential of Cytokines by Making them Context Dependent

Media

Life Science Leader

A Recipe for Start-Up Success with a Platform Technology

Media

In Vivo Pharma Intelligence

The Busiest Dealmakers of 2022

Media

Puget Sound Business Journal

Seattle biotech Bonum raises $93M Series A round

Media

Blog

A BD Checklist: Best Practices for Partnering with Pharma

Blog

Should My Biotech Startup Buy Or Produce The Proteins We Use?

Blog

Developing the Next Generation of Targeted, Conditionally Active Cytokine Therapeutics

Blog

Founder & CEO John Mulligan Shares Bonum Therapeutics’ “No Jerks” Approach to Hiring

Blog

6 Tips for Successful Drug Discovery Teamwork

Blog
2024
SYSTEMIC DELIVERY, LOCAL ACTIVITY

Press Releases

Bonum Therapeutics Announces a $93M Series A Financing to Advance a Novel and Validated Class of Conditionally Active Therapies

“We believe that this technology has broad potential and we are excited to apply it in new areas…”

Good Therapeutics Announces Acquisition of Conditionally Active PD-1-Regulated IL-2 Program by Roche

“Given Roche’s expertise in this field and broad capabilities in oncology, we believe they are a perfect choice for taking this important program forward…”

In the news

GeekWire

Seattle biotech startup born out of a Roche buyout lands $93M to advance therapies

Media

Genetic Engineering & Biotechnology News

From Good to Great: Bonum Therapeutics Raises $93M Series A with Allosterically Regulated Medicines

Media

Endpoints News

The crew that sold its lead IL-2 program to Roche is back with $93M to work on more next-gen I/O drugs

Media

Biocentury

Sequel company Bonum emerges in wake of Roche’s Good Tx acquisition

Media

BioWorld

Bonum to continue Good work after $250M cash acquisition deal with Roche

Media

Also seen in

Drug Discovery World

How to Get the Biopharma Deal You Want

Media

BioSpace

NextGen Class of 2024: Top Life Sciences Startups to Watch This Year

Media

Business of Biotech Podcast

IL-2 Program with Bonum’s Drs. John Mulligan and Neela Patel

Media

Rivervest

From Good to Great: Unlocking a biopharma platform’s full potential

Media

The Bio Report Podcast

Realizing the Therapeutic Potential of Cytokines by Making them Context Dependent

Media

Life Science Leader

A Recipe for Start-Up Success with a Platform Technology

Media

In Vivo Pharma Intelligence

The Busiest Dealmakers of 2022

Media

Puget Sound Business Journal

Seattle biotech Bonum raises $93M Series A round

Media

Blog

A BD Checklist: Best Practices for Partnering with Pharma

Blog

Should My Biotech Startup Buy Or Produce The Proteins We Use?

Blog

Developing the Next Generation of Targeted, Conditionally Active Cytokine Therapeutics

Blog

Founder & CEO John Mulligan Shares Bonum Therapeutics’ “No Jerks” Approach to Hiring

Blog

6 Tips for Successful Drug Discovery Teamwork

Blog